26732-20-7

Basic information

• Product Name: 1-BROMO-4-(ETHYLSULFONYL)BENZENE
• Synonyms: 1-BROMO-4-(ETHYLSULFONYL)BENZENE;1-Bromo-4-(ethylsulphonyl)benzene;1-Bromo-4-(ethanesulfonyl)benzene;Benzene,1-broMo-4-(ethylsulfonyl)-;1-Bromo-4-(ethylsulfonyl)
• CAS NO: 26732-20-7
• Molecular Formula: C₈H₉BrO₂S
• Molecular Weight: 249.12486
• Mol File: 26732-20-7.mol
• Article Data: 13

Chemical Properties

• Melting Point: 54-55
• Boiling Point: 357.828 °C at 760 mmHg
• Flash Point: 170.208 °C
• Appearance: /
• Density: 1.52 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.554
• CAS DataBase Reference: 1-BROMO-4-(ETHYLSULFONYL)BENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BROMO-4-(ETHYLSULFONYL)BENZENE(26732-20-7)
• EPA Substance Registry System: 1-BROMO-4-(ETHYLSULFONYL)BENZENE(26732-20-7)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 26732-20-7(Hazardous Substances Data)

Usage

General Description

1-Bromo-4-(ethylsulfonyl)benzene, also known as ethyl 4-bromobenzenesulfonate, is a chemical compound with the molecular formula C8H9BrO2S. It is a brominated aromatic compound which is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It can be produced through the reaction of 4-nitrobenzene and ethyl sulfide, followed by bromination. 1-BROMO-4-(ETHYLSULFONYL)BENZENE has several potential applications in the field of organic synthesis due to its ability to undergo various types of chemical reactions, such as nucleophilic substitution, elimination, and palladium-catalyzed coupling reactions. It is important to handle 1-bromo-4-(ethylsulfonyl)benzene with caution, as it is considered harmful if inhaled, and may cause skin and eye irritation.

InChI:InChI=1/C8H9BrO2S/c1-2-12(10,11)8-5-3-7(9)4-6-8/h3-6H,2H2,1H3

Upstream product

• 75-03-6 ethyl iodide 
• 106-53-6 para-bromobenzenethiol 
• 30506-30-0 1-bromo-4-ethylthiobenzene 
• 20035-08-9 sodium ethanesulfinate 
• 106-40-1 4-bromo-aniline 
• 2297-64-5 p-bromophenylsulfonyl hydrazide 
• 64-17-5 ethanol 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 30506-29-7 1-bromo-4-(ethylsulfinyl)benzene 

Downstream Products

• 1310492-88-6 3-((4-bromophenyl)thio)-2-phenylimidazo[1,2-a]pyridine 
• 1339944-54-5 5-Chloro-4-(1-(5-chloropyrimidin-2-yl)piperidin-4-yloxy)-1-(4-(ethylsulfonyl)phenyl)pyridin-2(1H)-one 
• 1339944-51-2 5-Chloro-1-(4-(ethylsulfonyl)phenyl)-4-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yloxy)pyridin-2(1H)-one 
• 1221236-89-0 4-bromo-1-(1-methylpropylsulfonyl)benzene 
• 1286238-53-6 3-amino-6-(4-(sec-butylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide 
• 1258324-56-9 (S)-tert-butyl 2-((S)-1-amino-3-(4'-(ethylsulfonyl)biphenyl-4-yl)-1-oxopropan-2-ylcarbamoyl)piperidine-1-carboxylate 
• 1080063-98-4 C₁₅H₂₀O₆S 

Relevant articles and documents

Visible-light-driven electron donor-acceptor complex induced sulfonylation of diazonium salts with sulfinates

This work reports an efficient sulfonylation reaction enabled by a visible-light-induced radical coupling reaction between phenyl/heterocyclic diazonium salts and sulfinates. Mechanistic experiments disclosed the formation of a versatile electron donor-acceptor (EDA) complex. This transformation is characterized by an easy operational procedure under mild conditions which avoids transition metals, ligands, catalysts, and oxidants.

A mild and chemoselective CALB biocatalysed synthesis of sulfoxides exploiting the dual role of AcOEt as solvent and reagent

A mild, chemoselective and sustainable biocatalysed synthesis of sulfoxides has been developed exploiting CALB and using AcOEt with a dual role of more environmentally friendly reaction solvent and enzyme substrate. A series of sulfoxides, including the drug omeprazole, have been synthesised in high yields and with excellent E-factors.

Dihydropyrrolopyridine inhibitors of ROR-gamma

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions co